Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial

Lancet

Volumn 357, Issue 9267, 2001, Pages 1478-1484

  Georgoulias, V ^a   Papadakis, E ^b   Alexopoulos, A ^c   Tsiafaki, X ^d   Rapti, A ^b   Veslemes, M ^e   Palamidas, Ph ^d   Vlachonikolis, I ^f  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c Immunology Laboratory   (Greece)

^d Sismanogllon General Hosptial of Athens   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

^f UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH; VOMITING;

EID: 0035849269     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04644-4     Document Type: Article

References (27)

1. Feigal EG, Christian M, Cheson B, et al. New chemotherapeutic agents in non-small-cell lung cancer. Semin Oncol 1993; 20: 185-201.
2. Souquet PJ, Chauvin F, Boissel JP, et al. Poly ehe m o therapy in advanced non-small-cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21.
3. Non-small-cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-909.
4. Albain KS, Growley JJ, Le Blanc M, et al. Survival determinants in extensive disease non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-26.
5. Leudke DW, Einhorn L, Ommara GA, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in non-small-cell lung cancer: a Southern Cancer Study Group trial. J Clin Oncol 1990; 8: 886-91.
6. Gridelli C, Perrone F, Palmeri S, et al. Mitomycin plus vindesine plus etopoide (MEV) versus mitomycin plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: a phase III multicenter randomized trial. Ann Oncol 1996; 7: 821-26.
7. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12: 1238-44.
8. 2 with prednisone premedication for patients with advanced non-small-cell lung cancer. Cancer 1995; 75: 968-72.
9. Abbratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. JClin Oncol 1994; 12: 1821-26.
10. Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small-cell lung cancer: a multicenter extended phase II study. Eur J Cancer 1996; 324: 243-48.
11. Georgoulias V, Androulakis N, Dimopoulos AM, et al. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol 1998; 9: 331-34.
12. Zalcberg J, Millward M, Bishop J, et al. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 1998; 16: 1948-53.
13. Anton A, Diaz-Fernandez N, Gonzalez Larriba JL, et al. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small-cell lung cancer (NSCLC). Lung Cancer 1998; 22: 139-48.
14. Lippe P, Tummarello D, Monterubbianesi MC, et al. Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase II study. Ann Oncol 1999; 10: 217-21.
15. Rizvi NA, Spiridonidis H, Davis Th, et al. Docetaxel and gemcitabine combinations in non-small cell lung cancer. Semin Oncol 1999; 26 (Suppl 16):S27-31.
16. Georgoulias V, Kouroussis Ch, Androulakis N, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 1999; 17: 914-20.
17. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
18. Altman GD. Practical statistics for medical research. London: Chapman and Hall, 1991.
19. Collett D. Modelling survival data in medical research. London: Chapman and Hall, 1994.
20. Armitage P, Berry G. Statistical methods in medical research, 3rd edn. Oxford: Blackwell Scientific, 1994.
21. Cox DR. The analysis of binary data. London: Methuen, 1970.
22. Gatzemeier U, Heckmanr M, Hossfeld DK, et al. A randomised trial of mitomycin-C/ifosfamide vs minomycin-C/vindesine, vs cisplatin/etoposide in advanced non-small cell lung cancer. Am J Clin Oncol 1991; 14: 405-11.
23. Kosmidis PA, Bacoyiannis C, Mylonakis N, et al. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non-small cell lung cancer (NSCLC): a preliminary analysis. Proc Am Soc Clin Oncol 2000; 19: 488.
24. Yamamoto N, Fukuoka M, Nakagawa K, et al. Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plusirinotecan in advanced non-small cell lung cancer (NSCLC): a West Japan Thoracic Oncology Group (WJTOG). Ann Oncol 2000; 11 (Suppl 4): S107.
25. Rodenhuis S, Slebos RJC, Evers SG, et al. K-ras oncogene activation on adenocarcinoma of the lung: frequency and possible clinical significance. Cancer Res 1998; 48: 5738-41.
26. Sklar MD. Increased resistance to cis-diamminedichloroplatinum in NIH-3T3 cells transformed by ras oncogenes. Cancer Res 1988; 48: 793-97.
27. Koo HM, McWilliams MJ, Alvord WG, et al. Ras oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine. Cancer Res 1999; 59: 6057-62